CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer.

CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer. Abstract Text:

Opioid agonists have a broad range of effects on cells of the immune system, including modulation of the inflammatory response, and opioid and chemokine receptors are co-expressed by many white cells. Hetero-oligomerization of the human DOP opioid and chemokine CXCR2 receptors could be detected following their co-expression by each of co-immunoprecipitation, three different resonance energy transfer techniques and the construction of pairs of individually inactive but potentially complementary receptor G-protein alpha subunit fusion proteins. Although DOP receptor agonists and a CXCR2 antagonist had no inherent affinity for the alternative receptor when either receptor was expressed individually, use of cells that expressed a DOP opioid receptor construct constitutively, and in which expression of a CXCR2 receptor construct could be regulated, demonstrated that the CXCR2 antagonist enhanced the function of DOP receptor agonists only in the presence of CXCR2. This effect was observed for both enkephalin- and alkaloid-based opioid agonists, and the effective concentrations of the CXCR2 antagonist reflected CXCR2 receptor occupancy. Entirely equivalent results were obtained in cells in which the native DOP opioid receptor was expressed constitutively and in which expression of the isolated CXCR2 receptor could be induced. These results indicate that a CXCR2 receptor antagonist can enhance the function of agonists at a receptor for which it has no inherent direct affinity by acting as an allosteric regulator of a receptor that is a heterodimer partner for the CXCR2 receptor. These results have novel and important implications for the development and use of small-molecule therapeutics.

CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: The Biochemical journal

VOLUME: 412

Page Numbers: 245-56

Journal Abbreviation: Biochem. J.

ISSN: 1470-8728

DAY: 1

MONTH: Jun

YEAR: 2008

CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 2984726

CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer.

AFFILIATION: Molecular Pharmacology Group, Division of Biochemistry and Molecular Biology, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow G12 8QQ, Scotland, U.K.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Biochem J

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer Related Publications

• A simple approach to test for interaction between intervention and an individual-level variable in community randomized trials.
• An instrument to level tissue in paraffin embedding.
• Analysis of the weak interactions of ADP-Unc104 and ADP-kinesin with microtubules and their inhibition by MAP2c.
• Antibodies that identify only the active conformation of Gi family G protein {alpha} subunits.
• Antibody-mediated protection against genital herpes simplex virus type 2 disease in mice by Fc gamma receptor-dependent and -independent mechanisms.
• Astrocyte and muscle-derived secreted factors differentially regulate motoneuron survival.
• CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer.
• Cannabinoids for the treatment of neuropathic pain: Clinical evidence.
• Chemical methods in the evaluation of human contamination.
• Constitutive Activity of the Cannabinoid CB1 Receptor Regulates the Function of Co-expressed Mu Opioid Receptors.
• Early resolution of herpes simplex virus type 2 infection of the murine genital tract involves stimulation of genital parenchymal cells by gamma interferon.
• Epizootiology of trypanosomiases: some aspects of mathematical modelling.
• Exogenous Hsc70, but not thermal preconditioning, confers protection to motoneurons subjected to oxidative stress.
• G protein coupling and ligand selectivity of the D2L and D3 dopamine receptors.
• G-protein-coupled receptors: an update.
• In vitro methods to prepare astrocyte and motoneuron cultures for the investigation of potential in vivo interactions.
• Lucky 13-microtubule depolymerisation by kinesin-13 motors.
• Mallory-Weiss syndrome with esophageal obstruction secondary to adherent intraluminal thrombus.
• Maternal employment, breastfeeding, and health: Evidence from maternity leave mandates.
• Mutations of beta-arrestin 2 that limit self-association also interfere with interactions with the beta(2)-adrenoceptor and the ERK1/2 MAPKs: implications for beta(2)-adrenoceptor signalling via the ERK1/2 MAPKs.
• New aspects of g-protein-coupled receptor signalling and regulation.
• Reactivity of DNA guanyl radicals with phenolate anions.
• Regulation of heat shock protein 70 release in astrocytes: role of signaling kinases.
• Some determinants of attrition in prospective studies on aging.
• The patient's point of view.
• Treatment of psychoneurosis; modified CO2 abreactive technique.
• Urology in a modern health centre.
• Visualisation of a kinesin-13 motor on microtubule end mimics.
• Warburg (HARD +/- E) syndrome without retinal dysplasia: case report and review.
• c-Jun N-terminal kinase signaling regulates events associated with both health and degeneration in motoneurons.